Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience.
Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience.
复制标题
DOI：
10.1016/j.jpeds.2011.10.038
复制
发表时间：
2012-05
影响因子：
5.1
通讯作者：
Anand, Ravinder
中科院分区：
文献类型：
--
作者：
Ng, Vicky L.;Alonso, Estella M.;Bucuvalas, John C.;Cohen, Geoff;Limbers, Christine A.;Varni, James W.;Mazariegos, George;Magee, John;McDiarmid, Susan V.;Anand, Ravinder
确定临床和健康相关的生活质量结果，并得出在美国和加拿大进行儿科肝移植 (LT) 10 年后仍存活的儿童的“理想”综合概况。这是一项多中心横断面分析，对登记在儿科肝移植研究数据库登记册中的 LT 存活超过 10 年的患者进行分析。总共确定了 167 名 10 年幸存者，他们都接受了每日免疫抑制治疗。与 LT 后病程相关的合并症包括移植后淋巴组织增生性疾病（5% 的患者）、肾功能障碍（9%）和线性生长受损（23%）。通过 PedsQL 4.0 通用核心量表评估的健康相关生活质量显示，与匹配的健康儿童相比，10 年幸存者的患者自我报告总量表得分较低（77.2 ± 12.9 与 84.9 ± 11.7；P < .001）。 LT 后 10 年，只有 32% 的患者在免疫抑制单一疗法下实现了首个同种异体移植稳定、正常生长和不存在常见的免疫抑制引起的后遗症的理想状况。儿科 LT 后的成功已经超越了患者的生存。随访时获得理想的综合概况为患者、家属和医疗保健提供者提供了在早期阶段确定更广泛结果的机会，最终有助于改善儿科 LT 后的结果。
To determine clinical and health-related quality of life outcomes, and to derive an “ideal” composite profile of children alive 10 years after pediatric liver transplantation (LT) performed in the US and Canada. This was a multicenter cross-sectional analysis characterizing patients enrolled in the Studies of Pediatric Liver Transplantation database registry who have survived >10 years from LT. A total of 167 10-year survivors were identified, all of whom received daily immunosuppression therapy. Comorbidities associated with the post-LT course included post-transplantation lymphoproliferative disease (in 5% of patients), renal dysfunction (9%), and impaired linear growth (23%). Health-related quality of life, as assessed by the PedsQL 4.0 Generic Core Scales, revealed lower patient self-reported total scale scores for 10-year survivors compared with matched healthy children (77.2 ± 12.9 vs 84.9 ± 11.7; P < .001). At 10 years post-LT, only 32% of patients achieved an ideal profile of a first allograft stable on immunosuppression monotherapy, normal growth, and absence of common immunosuppression-induced sequelae. Success after pediatric LT has moved beyond patient survival. Availability of an ideal composite profile at follow-up provides opportunities for patients, families, and healthcare providers to identify broader sets of outcomes at earlier stages, ultimately contributing to improved outcomes after pediatric LT.
登录
查看更多内容
影响因子：
3
作者：
Varni, JW;Seid, M;Kurtin, PS
通讯作者：
Kurtin, PS
影响因子：
2.6
作者：
Kamath, Binita M.;Olthoff, Kim M.
通讯作者：
Olthoff, Kim M.
影响因子：
8.8
作者：
Thuluvath, P. J.;Guidinger, M. K.;Pelletier, S. J.
通讯作者：
Pelletier, S. J.
影响因子：
8.8
作者：
Alonso, E. M.;Shepherd, R.;Anand, R.
通讯作者：
Anand, R.
影响因子：
8
作者：
Ng, Vicky Lee;Fecteau, Annie;Anand, Ravinder
通讯作者：
Anand, Ravinder